@article {Di Legge1446, author = {Alessia Di Legge and Ilaria Nausica Trivellizzi and Maria Cristina Moruzzi and Adele Pesce and Giovanni Scambia and Domenica Lorusso}, title = {Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer}, volume = {21}, number = {8}, pages = {1446--1451}, year = {2011}, doi = {10.1097/IGC.0b013e31822d754e}, publisher = {BMJ Specialist Journals}, abstract = {Background: Advanced or recurrent endometrial cancer is associated with a poor prognosis, and results obtained with systemic therapy are far from being impressive. Myocet is an interesting formulation of citrate conjugated doxorubicin encapsulated in nonpegylated liposomes. This phase 2 study was designed to evaluate the objective response rate and the toxicity profile of Myocet in women with advanced or recurrent endometrial cancer.Methods: Patients with diagnosis of advanced or recurrent endometrial cancer failing 1 previous carboplatin-paclitaxel chemotherapy were enrolled. Myocet was administered at the dose of 60 mg/m2 intravenously on day 1 every 4 weeks.Results: Eighteen patients were enrolled in our institution from September 2007 to January 2010. No complete or partial response was observed. Stable disease was registered in 5 patients (27.5\%). Median time to progression was 9 weeks. Median time to death was 24 weeks. Grade 3/4 anemia was reported in 2 patients (11\%). Grade 3/4 neutropenia was observed in 16.5\% and 44\% of patients, respectively. The major nonhematologic toxicities (grades 3/4) were fatigue (22\%), nausea, and vomiting (5.5\%).Conclusions: Myocet presents no activity, and only few stabilizations of disease of limited duration in this recurrent endometrial carcinoma population previously treated with platinum-taxane chemotherapy are reported.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/21/8/1446}, eprint = {https://ijgc.bmj.com/content/21/8/1446.full.pdf}, journal = {International Journal of Gynecologic Cancer} }